Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Solid tumours |
Dose: Intravenous – 4-10 mg (0.06-0.15 mg/kg) Frequency: given at 1-6 weekly intervals Note: Intervals depend on whether other drugs are given in combination and on bone marrow recovery. |
|
Indication: Solid tumours |
Dose: Intravenous – 10 mg/m2 of body surface area Note: Course being repeated at intervals for as long as required. Often required for a satisfactory response when used alone or in combination. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Serum creatinine greater than 1.7 mg/dL |
Dose: Not specified Note: Avoid use |
|
Condition: Creatinine Clearance less than 10 mL/min |
Dose: Not specified Note: Decrease dose by 25% |
Administration
- For IV use only
- Must be given slowly
Side Effect
- Hemolytic uremic syndrome (≤15%)
- Myelosuppression (64%)
- Nausea/vomiting (14%)
- Fever (14%)
- Stomatitis (4%)
- Increased serum creatinineeatinine (2%)
- Mucous membrane toxicity (4%)
- Fatigue
- Pulmonary toxicity
- Dyspnea
- Cystitis
- Interstitial fibrosis
- Nephrotoxicity
- Amenorrhea
- Alopecia
- Myelosuppression
- haemolytic-uraemic syndrome
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Doxorubicin
|
Increased incidence of cardiotoxicity
|
|
Fluorouracil
|
Potentially Fatal: Increased risk of intravascular haemolysis and renal failure
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Low platelet count (<100,000/mm3)
|
Bleeding risk
|
|
Coagulation disorders
|
Severe bleeding risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Powder for injection: Store between 15-30°C. Protect from light.
Reconstituted solution: Stable for 1 wk when stored between 15-25°C and 2 wk when stored between 2-8°C.
Reconstituted solution: Stable for 1 wk when stored between 15-25°C and 2 wk when stored between 2-8°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.